Inmune Bio (INMB) Receivables - Other (2021 - 2026)
Inmune Bio (INMB) posted Receivables - Other of $291000.0 for Q1 2026, up 157.85% sequentially from -$503000.0 in Q4 2025, and up 118.8% YoY from $133000.0 in Q1 2025.
Inmune Bio (INMB) Receivables - Other (2021 - 2026) Analysis & Trends
Inmune Bio has reported Receivables - Other for 6 years, with the latest figure at $291000.0 in Q1 2026.
- Quarterly Receivables - Other rose 118.8% year-over-year to $291000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $291000.0 (up 118.8% YoY) and the FY2025 annual result came in at $257000.0, up 183.17% from the prior year.
- Receivables - Other grew to $291000.0 in Q1 2026 per INMB's latest filing, from -$503000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $760000.0 in Q3 2025 and troughed at -$503000.0 in Q4 2025.
- A 5-year average of $163882.4 and a median of $133000.0 in 2025 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2024 and 2025: Receivables - Other soared 1538.24% in 2024, then slumped 506.02% in 2025.
- Over 5 years, Receivables - Other stood at $248000.0 in 2022, then jumped by 45.56% to $361000.0 in 2023, then slumped by 122.99% to -$83000.0 in 2024, then plunged by 506.02% to -$503000.0 in 2025, then surged by 157.85% to $291000.0 in 2026.
- According to Business Quant data, Receivables - Other over the past three periods registered $291000.0, -$503000.0, and $760000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 354,000.00 |
| Jun 30, 2026 | 354,000.00 |
| Mar 31, 2026 | 291,000.00 |
| Mar 31, 2026 | 291,000.00 |
| Dec 31, 2025 | -503,000.00 |
| Dec 31, 2025 | -503,000.00 |
| Sep 30, 2025 | 760,000.00 |
| Sep 30, 2025 | 760,000.00 |
| Jun 30, 2025 | 550,000.00 |
| Jun 30, 2025 | 550,000.00 |
| Mar 31, 2025 | 133,000.00 |
| Mar 31, 2025 | 133,000.00 |
| Dec 31, 2024 | -83,000.00 |
| Dec 31, 2024 | -83,000.00 |
| Sep 30, 2024 | 545,000.00 |
| Sep 30, 2024 | 545,000.00 |
| Jun 30, 2024 | 590,000.00 |
| Jun 30, 2024 | 590,000.00 |
| Mar 31, 2024 | 557,000.00 |
| Mar 31, 2024 | 557,000.00 |